The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five new medicines for approval during its March 24–27, 2025 meeting5.
Of these five, three are biosimilars:
Jubereq (denosumab), Qoyvolma (ustekinumab), and Osvyrti (denosumab)5.
Xoanacyl (ferric citrate coordination complex) was recommended for the treatment of hyperphosphatemia and iron deficiency in adults with chronic kidney disease5.
Ryjunea (atropine) received a positive opinion for the slowing of myopia progression in children aged 3 to 145.
Seven additional medicines were recommended for extensions of their therapeutic indications5.
The CHMP also recently reconsidered Eli Lilly’s Kisunla, but no specific details of the outcome or context are provided in the current search results.
These recommendations are part of the EMA's ongoing efforts to address both unmet medical needs and expand access to biosimilar therapies in Europe5.
Sources:
5. https://www.pharmtech.com/view/ema-recommends-five-new-medicines-approval